2025-01-012025-12-312025-12-31false07166638The Pharmacy Consultancy Limited2026-05-14falseiso4217:GBPxbrli:pure071666382024-12-31071666382025-12-31071666382025-01-012025-12-31071666382023-12-31071666382024-12-31071666382024-01-012024-12-3107166638bus:SmallEntities2025-01-012025-12-3107166638bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3107166638bus:FullAccounts2025-01-012025-12-3107166638bus:PrivateLimitedCompanyLtd2025-01-012025-12-3107166638core:WithinOneYear2025-12-3107166638core:AfterOneYear2025-12-3107166638core:WithinOneYear2024-12-3107166638core:AfterOneYear2024-12-3107166638core:ShareCapital2025-12-3107166638core:SharePremium2025-12-3107166638core:RevaluationReserve2025-12-3107166638core:OtherReservesSubtotal2025-12-3107166638core:RetainedEarningsAccumulatedLosses2025-12-3107166638core:ShareCapital2024-12-3107166638core:SharePremium2024-12-3107166638core:RevaluationReserve2024-12-3107166638core:OtherReservesSubtotal2024-12-3107166638core:RetainedEarningsAccumulatedLosses2024-12-3107166638core:LandBuildings2025-12-3107166638core:PlantMachinery2025-12-3107166638core:Vehicles2025-12-3107166638core:FurnitureFittings2025-12-3107166638core:OfficeEquipment2025-12-3107166638core:NetGoodwill2025-12-3107166638core:IntangibleAssetsOtherThanGoodwill2025-12-3107166638core:ListedExchangeTraded2025-12-3107166638core:UnlistedNon-exchangeTraded2025-12-3107166638core:LandBuildings2024-12-3107166638core:PlantMachinery2024-12-3107166638core:Vehicles2024-12-3107166638core:FurnitureFittings2024-12-3107166638core:OfficeEquipment2024-12-3107166638core:NetGoodwill2024-12-3107166638core:IntangibleAssetsOtherThanGoodwill2024-12-3107166638core:ListedExchangeTraded2024-12-3107166638core:UnlistedNon-exchangeTraded2024-12-3107166638core:LandBuildings2025-01-012025-12-3107166638core:PlantMachinery2025-01-012025-12-3107166638core:Vehicles2025-01-012025-12-3107166638core:FurnitureFittings2025-01-012025-12-3107166638core:OfficeEquipment2025-01-012025-12-3107166638core:NetGoodwill2025-01-012025-12-3107166638core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3107166638core:ListedExchangeTraded2025-01-012025-12-3107166638core:UnlistedNon-exchangeTraded2025-01-012025-12-3107166638core:MoreThanFiveYears2025-01-012025-12-3107166638core:Non-currentFinancialInstruments2025-12-3107166638core:Non-currentFinancialInstruments2024-12-3107166638dpl:CostSales2025-01-012025-12-3107166638dpl:DistributionCosts2025-01-012025-12-3107166638core:LandBuildings2025-01-012025-12-3107166638core:PlantMachinery2025-01-012025-12-3107166638core:Vehicles2025-01-012025-12-3107166638core:FurnitureFittings2025-01-012025-12-3107166638core:OfficeEquipment2025-01-012025-12-3107166638dpl:AdministrativeExpenses2025-01-012025-12-3107166638core:NetGoodwill2025-01-012025-12-3107166638core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3107166638dpl:GroupUndertakings2025-01-012025-12-3107166638dpl:ParticipatingInterests2025-01-012025-12-3107166638dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-012025-12-3107166638core:ListedExchangeTraded2025-01-012025-12-3107166638dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-012025-12-3107166638core:UnlistedNon-exchangeTraded2025-01-012025-12-3107166638dpl:CostSales2024-01-012024-12-3107166638dpl:DistributionCosts2024-01-012024-12-3107166638core:LandBuildings2024-01-012024-12-3107166638core:PlantMachinery2024-01-012024-12-3107166638core:Vehicles2024-01-012024-12-3107166638core:FurnitureFittings2024-01-012024-12-3107166638core:OfficeEquipment2024-01-012024-12-3107166638dpl:AdministrativeExpenses2024-01-012024-12-3107166638core:NetGoodwill2024-01-012024-12-3107166638core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3107166638dpl:GroupUndertakings2024-01-012024-12-3107166638dpl:ParticipatingInterests2024-01-012024-12-3107166638dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3107166638core:ListedExchangeTraded2024-01-012024-12-3107166638dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3107166638core:UnlistedNon-exchangeTraded2024-01-012024-12-3107166638core:NetGoodwill2025-12-3107166638core:IntangibleAssetsOtherThanGoodwill2025-12-3107166638core:LandBuildings2025-12-3107166638core:PlantMachinery2025-12-3107166638core:Vehicles2025-12-3107166638core:FurnitureFittings2025-12-3107166638core:OfficeEquipment2025-12-3107166638core:AfterOneYear2025-12-3107166638core:WithinOneYear2025-12-3107166638core:ListedExchangeTraded2025-12-3107166638core:UnlistedNon-exchangeTraded2025-12-3107166638core:ShareCapital2025-12-3107166638core:SharePremium2025-12-3107166638core:RevaluationReserve2025-12-3107166638core:OtherReservesSubtotal2025-12-3107166638core:RetainedEarningsAccumulatedLosses2025-12-3107166638core:NetGoodwill2024-12-3107166638core:IntangibleAssetsOtherThanGoodwill2024-12-3107166638core:LandBuildings2024-12-3107166638core:PlantMachinery2024-12-3107166638core:Vehicles2024-12-3107166638core:FurnitureFittings2024-12-3107166638core:OfficeEquipment2024-12-3107166638core:AfterOneYear2024-12-3107166638core:WithinOneYear2024-12-3107166638core:ListedExchangeTraded2024-12-3107166638core:UnlistedNon-exchangeTraded2024-12-3107166638core:ShareCapital2024-12-3107166638core:SharePremium2024-12-3107166638core:RevaluationReserve2024-12-3107166638core:OtherReservesSubtotal2024-12-3107166638core:RetainedEarningsAccumulatedLosses2024-12-3107166638core:NetGoodwill2023-12-3107166638core:IntangibleAssetsOtherThanGoodwill2023-12-3107166638core:LandBuildings2023-12-3107166638core:PlantMachinery2023-12-3107166638core:Vehicles2023-12-3107166638core:FurnitureFittings2023-12-3107166638core:OfficeEquipment2023-12-3107166638core:AfterOneYear2023-12-3107166638core:WithinOneYear2023-12-3107166638core:ListedExchangeTraded2023-12-3107166638core:UnlistedNon-exchangeTraded2023-12-3107166638core:ShareCapital2023-12-3107166638core:SharePremium2023-12-3107166638core:RevaluationReserve2023-12-3107166638core:OtherReservesSubtotal2023-12-3107166638core:RetainedEarningsAccumulatedLosses2023-12-3107166638core:AfterOneYear2025-01-012025-12-3107166638core:WithinOneYear2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:CostValuation2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3107166638core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3107166638core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-3107166638core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3107166638core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3107166638core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3107166638core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3107166638core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3107166638core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3107166638core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3107166638core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3107166638core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3107166638bus:Director12025-01-012025-12-3107166638bus:Director22025-01-012025-12-3107166638core:FurnitureFittingsToolsEquipment2024-12-3107166638core:FurnitureFittingsToolsEquipment2025-01-012025-12-3107166638core:FurnitureFittingsToolsEquipment2025-12-31

The Pharmacy Consultancy Limited

Registered Number
07166638
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2025

The Pharmacy Consultancy Limited
Company Information
for the year from 1 January 2025 to 31 December 2025

Directors

Mr KA Nichols
Mrs S Nichols

Registered Address

The Stables
Church Walk
Daventry
NN11 4BL

Registered Number

07166638 (England and Wales)
The Pharmacy Consultancy Limited
Balance Sheet as at
31 December 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets3839471
839471
Current assets
Stocks47,59530,160
Debtors385369
Cash at bank and on hand13,455-
21,43530,529
Creditors amounts falling due within one year5(9,267)(9,092)
Net current assets (liabilities)12,16821,437
Total assets less current liabilities13,00721,908
Provisions for liabilities(210)(118)
Net assets12,79721,790
Capital and reserves
Called up share capital1,0001,000
Profit and loss account11,79720,790
Shareholders' funds12,79721,790
The financial statements were approved and authorised for issue by the Board of Directors on 14 May 2026, and are signed on its behalf by:
Mr KA Nichols
Director
Mrs S Nichols
Director

Registered Company No. 07166638
The Pharmacy Consultancy Limited
Notes to the Financial Statements
for the year ended 31 December 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Judgements and key sources of estimation uncertainty
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. These critical accounting judgements and estimations are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. The critical judgements made by management that have a significant effect on the amounts recognised in the financial statements are described below.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)Straight line (years)
Fixtures and fittings20-
Office Equipment-33.33
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20252024
Average number of employees during the year22
3.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 January 254,3344,2068,540
Additions-877877
Disposals(4,334)(3,883)(8,217)
At 31 December 25-1,2001,200
Depreciation and impairment
At 01 January 254,0244,0458,069
Charge for year61199260
On disposals(4,085)(3,883)(7,968)
At 31 December 25-361361
Net book value
At 31 December 25-839839
At 31 December 24310161471
4.Stocks

2025

2024

££
Work in progress7,59530,160
Total7,59530,160
5.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables703553
Bank borrowings and overdrafts1,2063,404
Taxation and social security5,9583,735
Accrued liabilities and deferred income1,4001,400
Total9,2679,092